1 Min Read
July 13 (Reuters) - Mallinckrodt Plc:
* Mallinckrodt phase 3 Terlipressin trial achieves its enrollment target ahead of schedule Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.